Brought to you by 
Precision Therapeutics raises $43mm in new financing round
20 Nov 2008
Executive Summary
Precision Therapeutics (develops tests that help predict drug response) raised $43mm in an undisclosed venture round led by new investor Longitude Venture Partners. Returning backers Adams Capital Management, Quaker BioVentures, Birchmere Ventures, Techno Venture Management, and Draper Triangle Ventures also participated. Precision will use the funds to develop and commercialize its ChemoFx drug response marker test for chemotherapy patients.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Precision Therapeutics raises $43mm in new financing round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice